Danielle Erin Lann, MD | |
19 Davis Ave Fl 2, Neptune, NJ 07753-4488 | |
(732) 776-4770 | |
(732) 776-3763 |
Full Name | Danielle Erin Lann |
---|---|
Gender | Female |
Speciality | Endocrinology |
Experience | 21 Years |
Location | 19 Davis Ave Fl 2, Neptune, New Jersey |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417116682 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 25MA08612500 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Jersey Shore University Medical Center | Neptune, NJ | Hospital |
Ocean Medical Center | Brick, NJ | Hospital |
Riverview Medical Center | Red bank, NJ | Hospital |
Bayshore Medical Center | Holmdel, NJ | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
Polymorphisms in the kallikrein7 and kallikrein10 genes are associated with the development and progression of oral squamous cell carcinoma, a study in Taiwanese men indicates.
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.
› Verified 5 days ago
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
Polymorphisms in the kallikrein7 and kallikrein10 genes are associated with the development and progression of oral squamous cell carcinoma, a study in Taiwanese men indicates.
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.
› Verified 5 days ago
Entity Name | Hackensack Meridian Health Medical Group - Complex Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1154379626 PECOS PAC ID: 0446272298 Enrollment ID: O20060109000000 |
News Archive
Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
Polymorphisms in the kallikrein7 and kallikrein10 genes are associated with the development and progression of oral squamous cell carcinoma, a study in Taiwanese men indicates.
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Danielle Erin Lann, MD 19 Davis Ave Fl 2, Neptune, NJ 07753-4488 Ph: (732) 776-4770 | Danielle Erin Lann, MD 19 Davis Ave Fl 2, Neptune, NJ 07753-4488 Ph: (732) 776-4770 |
News Archive
Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
Polymorphisms in the kallikrein7 and kallikrein10 genes are associated with the development and progression of oral squamous cell carcinoma, a study in Taiwanese men indicates.
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.
› Verified 5 days ago
Hani Naser, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4483 Fax: 732-776-4798 | |
Dr. Adam Chaim Kaplan, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3990 Fax: 732-897-3997 | |
Jose Fune, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3995 Fax: 732-897-3997 | |
Dr. Daniel Mark Shenouda, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 908-217-3023 Fax: 732-776-4798 | |
Dr. Kathleen King Casey, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3995 Fax: 732-897-3997 | |
Philip Willie Bankole Clarkson, M.D Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4483 Fax: 732-776-4798 | |
Kelly West Fitzpatrick, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 2, Neptune, NJ 07753 Phone: 732-367-1535 Fax: 732-367-9514 |